Previous Close | 3.42 |
1-Year Change | 91.06% |
6-Months Change | -42.9% |
3-Months Change | -47.38% |
Moving Avg (50d) | 4.5758 |
Moving Avg (200d) | 5.2056 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.28B |
Beta (3-Years) | 2.41 |
Revenue Growth (ttm) | -0.18% |
Net Profit Margin (ttm) | -82377.52% |
Return On Assets (ttm) | -105.92% |
EPS (ttm) | -1.05 |
PE Ratio (ttm) | -3.26 |
Dividend Yield | % |
Asset Description: | ImmunityBio, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2024-09-16 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
3.488 | 3.591 | 3.659 | 3.762 | 3.933 | 4.104 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |